請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65494
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林?輝(Feng-Huei Lin) | |
dc.contributor.author | Hung-I Lin | en |
dc.contributor.author | 林弘翊 | zh_TW |
dc.date.accessioned | 2021-06-16T23:46:29Z | - |
dc.date.available | 2015-07-31 | |
dc.date.copyright | 2012-07-31 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-07-23 | |
dc.identifier.citation | [1] Department of Health, Executive Yuan, R.O.C.(TAIWAN)
[2] Wolfgang Arthur Schulz 'Molecular biology of human cancers : an advanced student's textbook' Springer, 2005 [3] Armstrong, P., J. Congleton, et al. 'Guidelines on the selection of patients with lung cancer for surgery.' Thorax 56(2): 89-108, 2001 [4] Alexakis, N., C. Halloran, et al. 'Current standards of surgery for pancreatic cancer.' British Journal of Surgery 91(11): 1410-1427, 2004 [5] Kurtz, J. 'Oral chemotherapy in colorectal cancer treatment: review of the literature.' European Journal of Internal Medicine 14(1): 18-25, 2003 [6] Han, E., P. Lin, et al. 'Current Status on Biologic Therapies in the Treatment of Epithelial Ovarian Cancer.' Current treatment options in oncology 10(1): 54-66, 2009 [7] Baxevanis, C., S. Perez, et al. 'Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.' Cancer Immunology, Immunotherapy 58(3): 317-324, 2009 [8] Rodel, C. 'Current Status of Radiation Therapy and Combined-Modality Treatment for Bladder Cancer.' Strahlentherapie und Onkologie 180(11): 701-709, 2004 [9] Hall, E. J. 'Intensity-modulated radiation therapy, protons, and the risk of second cancers.' International Journal of Radiation Oncology Biology Physics 65(1): 1-7, 2006 [10] Song, C. W. 'Effect of local hyperthermia on blood flow and microenvironment: A review.' Cancer Research 44(10): 4721s-4730s, 1984 [11] Eric J. Hall and Amato J. Giaccia 'Radiobiology for the radiologist', 6th edition, Philadelphia : Lippincott Williams & Wilkins, 2006 [12] Dewey, W. C., L. E. Hopwood, et al. 'Cellular responses to combinations of hyperthermia and radiation.' Radiology 123(2): 463-474, 1977 [13] Gerner, E. W. and M. J. Schneider 'Induced thermal resistance in HeLa cells.' Nature 256(5517): 500-502, 1975 [14] M. Urano 'Kinetics of thermotolerance in normal and tumor tissues: a review.' Cancer research 46 474-482, 1986 [15] Moroz, P., S. K. Jones, et al. 'Status of hyperthermia in the treatment of advanced liver cancer.' Journal of Surgical Oncology 77(4): 259-269, 2001 [16] Wust, P., B. Hildebrandt, et al. 'Hyperthermia in combined treatment of cancer.' Lancet Oncology 3(8): 487-497, 2002 [17] Prasad, N. K., K. Rathinasamy, et al. 'Mechanism of cell death induced by magnetic hyperthermia with nanoparticles of γ-MnxFe2-xO3 synthesized by a single step process.' Journal of Materials Chemistry 17(48): 5042-5051, 2007 [18] Li, Z., M. Kawashita, et al. 'Magnetite nanoparticles with high heating efficiencies for application in the hyperthermia of cancer.' Materials Science and Engineering C 30(7): 990-996, 2010 [19] Elsherbini, A. A. M., M. Saber, et al. 'Magnetic nanoparticle-induced hyperthermia treatment under magnetic resonance imaging.' Magnetic Resonance Imaging 29(2): 272-280, 2011 [20] Ito, A., F. Matsuoka, et al. 'Heat shock protein 70 gene therapy combined with hyperthermia using magnetic nanoparticles.' Cancer Gene Therapy 10(12): 918-925, 2003 [21] Ito, A., F. Matsuoka, et al. 'Antitumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma.' Cancer Immunology, Immunotherapy 53(1): 26-32, 2004 [22] Ito, A., M. Shinkai, et al. 'Medical application of functionalized magnetic nanoparticles.' Journal of Bioscience and Bioengineering 100(1): 1-11, 2005 [23] Liu, T. Y., S. H. Hu, et al. 'Biomedical nanoparticle carriers with combined thermal and magnetic responses.' Nano Today 4(1): 52-65, 2009 [24] Mornet, S., S. Vasseur, et al. 'Magnetic nanoparticle design for medical applications.' Progress in Solid State Chemistry 34(2-4): 237-247, 2006 [25] Taylor, A., Y. Krupskaya, et al. 'Cisplatin-loaded carbon-encapsulated iron nanoparticles and their in vitro effects in magnetic fluid hyperthermia.' Carbon 48(8): 2327-2334, 2010 [26] Singh, N., G. J. S. Jenkins, et al. 'Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). ' Nano Reviews 1: 5358, 2010 [27] Chalkidou, A., K. Simeonidis, et al. 'In vitro application of Fe/MgO nanoparticles as magnetically mediated hyperthermia agents for cancer treatment.' Journal of Magnetism and Magnetic Materials 323(6): 775-780, 2011 [28] Wang, T. W., H. C. Wu, et al. 'The development of magnetic degradable DP-Bioglass for hyperthermia cancer therapy.' Journal of Biomedical Materials Research - Part A 83(3): 828-837, 2007 [29] Wu, H. C., T. W. Wang, et al. 'A novel biomagnetic nanoparticle based on hydroxyapatite.' Nanotechnology 18(16), 2007 [30] Hou, C. H., S. M. Hou, et al. 'The in vivo performance of biomagnetic hydroxyapatite nanoparticles in cancer hyperthermia therapy.' Biomaterials 30(23-24): 3956-3960, 2009 [31] Hou, C. h., C. w. Chen, et al. 'The fabrication and characterization of dicalcium phosphate dihydrate-modified magnetic nanoparticles and their performance in hyperthermia processes in vitro.' Biomaterials 30(27): 4700-4707, 2009 [32] Pankhurst, Q. A., J. Connolly, et al. 'Applications of magnetic nanoparticles in biomedicine.' Journal of Physics D: Applied Physics 36(13): R167-R181, 2003 [33] Mornet, S., S. Vasseur, et al. 'Magnetic nanoparticle design for medical diagnosis and therapy.' Journal of Materials Chemistry 14(14): 2161-2175, 2004 [34] Leslie-Pelecky, D. L. and R. D. Rieke 'Magnetic Properties of Nanostructured Materials.' Chemistry of Materials 8(8): 1770-1783, 1996 [35] Ritossa, F. 'A new puffing pattern induced by temperature shock and DNP in drosophila.' Experientia 18(12): 571-573, 1962 [36] Khalil, A. A., N. F. Kabapy, et al. 'Heat shock proteins in oncology: Diagnostic biomarkers or therapeutic targets?' Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1816(2): 89-104, 2011 [37] Soo, E. T. L., G. W. C. Yip, et al. 'Heat shock proteins as novel therapeutic targets in cancer.' In Vivo 22(3): 311-316, 2008 [38] Molecular Biology of the Cell. 4th edition, New York: Garland Science, 2002 [39] Bishop, S. C., J. A. Burlison, et al. 'Hsp90: A novel target for the disruption of multiple signaling cascades.' Current Cancer Drug Targets 7(4): 369-388, 2007 [40] Sreedhar, A. S. and P. Csermely 'Heat shock proteins in the regulation of apoptosis: New strategies in tumor therapy - A comprehensive review.' Pharmacology and Therapeutics 101(3): 227-257, 2004 [41] Beere, H. M. 'Death versus survival: Functional interaction between the apoptotic and stress-inducible heat shock protein pathways.' Journal of Clinical Investigation 115(10): 2633-2639, 2005 [42] Beere, H. M. ''The stress of dying': The role of heat shock proteins in the regulation of apoptosis.' Journal of Cell Science 117(13): 2641-2651, 2004 [43] Fiers, W., R. Beyaert, et al. 'More than one way to die: Apoptosis, necrosis and reactive oxygen damage.' Oncogene 18(54): 7719-7730, 1999 [44] Edinger, A. L. and C. B. Thompson 'Death by design: Apoptosis, necrosis and autophagy.' Current Opinion in Cell Biology 16(6): 663-669, 2004 [45] Kroemer, G., L. Galluzzi, et al. 'Classification of cell death: Recommendations of the Nomenclature Committee on Cell Death 2009.' Cell Death and Differentiation 16(1): 3-11, 2009 [46] Raffray, M. and G. M. Cohen 'Apoptosis and necrosis in toxicology: A continuum or distinct modes of cell death?' Pharmacology and Therapeutics 75(3): 153-177, 1997 [47] 林麗娟 'X 光繞射原理及其應用' 工業材料 86 100-109, 1994 [48] 楊鴻昌 '最敏感的感測元件SQUID及其前瞻性應用' 物理雙月刊 24(5): 652-666, 2002 [49] Zhao, Q.-L., Y. Fujiwara, et al. 'Mechanism of cell death induction by nitroxide and hyperthermia.' Free Radical Biology and Medicine 40(7): 1131-1143, 2006 [50] Gorman, A. M., Heavey, B., et al. 'Antioxidant-mediated inhibition of the heat shock response leads to apoptosis.' FEBS Letters 445(1): 98-102, 1999 [51] Samali, A., Holmberg, C. I., et al. 'Thermotolerance and cell death are distinct cellular responses to stress: dependence on heat shock proteins.' FEBS Letters 461(3): 306-10, 1999 [52] Samali, A., Robertson, J. D., et al. 'Hsp27 protects mitochondria of thermotolerant cells against apoptotic stimuli.' Cell Stress and Chaperones 6(1): 49-58, 2001 [53] Sharif-Khatibi, L., A. Kariminia, et al. 'Hyperthermia induces differentiation without apoptosis in permissive temperatures in human erythroleukaemia cells.' International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 23(8): 645-655, 2007 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65494 | - |
dc.description.abstract | 磁性氫氧基磷灰石是一種生物相容性良好的材料,利用共沉法可順利合成磁性氫氧基磷灰石,且不破壞氫氧基磷灰石的結構,磁性氫氧基磷灰石具備超順磁的特性,於高周波加熱器作用下,可快速升溫至熱療所需溫度 ( 42 ~ 47℃ ) ,非常適合當作熱療之磁性材料。
細胞與磁性氫氧基磷灰石共養後,會胞吞磁性氫氧基磷灰石,利用高周波加熱器使磁性氫氧基磷灰石於細胞內發熱,達到熱療之效果。人類纖維母細胞 ( human fibroblast, HF ) 以磁性氫氧基磷灰石進行熱療之處理 ( 43℃ 持續 30 分鐘 ) ,熱休克蛋白-70 ( heat shock protein 70, HSP70 ) 的表現量在 24 小時內會持續穩定上升,保護及修復 HF 因熱處理所受到的傷害;以相同熱療條件處理肺癌細胞 ( A-549 ) 與骨癌細胞 ( MG-63 ) , A-549 在熱處理後 6 小時開始表現熱休克蛋白-27 ( heat shock protein 27, HSP27 ) ,然而 HSP27 的表現量在熱處理後 12 與 24 小時逐漸減少,無法有效的彌平熱所造成 A-549 的傷害; MG-63 在熱處理後 0 小時表現 HSP70 與熱休克蛋白-90 ( heat shock protein 90, HSP90 ),立即保護 MG-63 因熱所造成的損傷,但在熱處理後 6 小時、 12 小時與 24 小時, HSP70 與 HSP90 並無明顯表現,無法持續的修復 MG-63 的損傷,導致 MG-63 在熱處理後 12 小時其生長停滯。 細胞死亡分為凋亡與壞死,利用膜外翻、 DNA 斷裂與 procaspase-3 活化的方式,可分辨細胞走向凋亡亦或壞死。 HF 在熱處理後因為 HSP70 表現量的穩定上升,在 24 小時其凋亡細胞佔 8.3% ± 0.85% ,壞死細胞佔 5.1% ± 0.57% , A-549 因 HSP27 的表現量在 24 小時逐漸減少,在 24 小時其凋亡細胞佔 57.96% ± 5.09% ,壞死細胞佔 26.86% ± 1.38% , MG-63 雖因熱能立即表現 HSP70 與 HSP90 ,但在 24 小時 HSP 並無明顯表現,在 24 小時凋亡細胞佔 60.35% ± 5.85% ,壞死細胞佔 4.2% ±0.85% 。在熱處理後 6 小時, HF 、 A-549 與 MG-63 皆觀測到 DNA 斷裂的情形。 HF 因 HSP70 的表現量穩定上升,故只在熱處理後 0 小時觀測到 procaspase-3 被活化, A-549 因 HSP27 在熱處理後 6 小時才逐漸被表現,其 procaspase-3 在熱處理後 0 小時明顯被活化, MG-63 因 HSP70 與 HSP90 迅速被熱所誘導表現,所以在熱處理後 0 小時並無 procaspase-3 被活化,然而 HSP70 與 HSP90 無法持續表現,故在熱處理後 6 與 12 小時可觀察到 procaspase-3 被活化。 | zh_TW |
dc.description.abstract | Magnetic hydroxyapatite ( mHAP ) is a material with good biocompatibility. By using the co-precipitation method, mHAP can be easily synthesized and kept the structure of hydroxyapatite ( HAP ). mHAP is super-paramagnetic and can be rapidly raised to the temperature of hyperthermia ( 42 ~ 47℃ ) by using the high frequency inductive heat generator. Therefore mHAP is very suitable to magnetic material for hyperthermia.
When cells cultured with mHAP, the cells would engulf some mHAP by endocytosis process. By using the high frequency inductive heat generator, mHAP generated heat in the cells to make the effects of hyperthermia. Treating the human fibroblast ( HF ) with the mHAP-induced hyperthermia ( 43℃ for 30 minutes ), the expression of heat shock protein 70 ( HSP70 ) stably increased in 24 hours in order to protect and repair the damages caused by hyperthermia. The same hyperthermia condition was treated to lung adenocarcinoma cells ( A-549 ) and osteosarcoma cells ( MG-63 ), the A-549 cells expressed heat shock protein 27 ( HSP27 ) at 6-hour after the heat treatment but the expression of HSP27 was gradually decreased at 12-hours and 24-hours. Therefore the damages of A-549 cells caused by hyperthermia could not be effectively repaired. MG-63 cells immediately expressed HSP70 and heat shock protein 90 ( HSP90 ) at 0-hour after hyperthermia in order to protect the cells from the heat damages. However, there was no obvious expression of HSP70 and HSP90 at 6-hours, 12-hours and 24-hours after hyperthermia. Therefore the repairs could not be sustained, which caused the growth arrest of MG-63 cells at 12-hours after hyperthermia. Cell death can be classified as apoptosis and necrosis. By using the cell membrane externalization, DNA fragmentation and procaspase-3 activation, we could distinguish the cell death was through apoptosis or necrosis. After hyperthermia, the apoptotic cells of HF at 24-hours were 8.3% ± 0.85% and the necrotic cells were 5.1% ± 0.57% due to the stably increased HSP70. Because the expression of HSP27 gradually decreased at 24-hours, the apoptotic cells of A-549 were 57.96% ± 5.09% and the necrotic cells were 26.86% ± 1.38%. MG-63 cells expressed HSP70 and HSP90 immediately but no obvious expressions at 24-hours after hyperthermia. Therefore the apoptotic cells at 24-hours were 60.35% ± 5.85% and the necrotic cells were 4.2% ±0.85%. 6 hours after hyperthermia, we could observe that the DNA of HF cells, A-549 cells and MG-63 cells was degraded into fragments. The procaspase-3 of HF cells did not be activated at 6-hours and 24-hours after hyperthermia because HSP70 was stably increased and cells were protected from damages. Because the HSP27 of A-549 cells was slowly and gradually expressed at 6-hours after hyperthermia, the procaspase-3 was obviously activated at 0-hour and 6-hours. On the other hand, the HSP70 and HSP90 of MG-63 cells were rapidly induced by hyperthermia so the procaspase-3 was not activated at 0-hour after hyperthermia. But the HSP70 and HSP90 could not be expressed consecutively, and hence the procaspase-3 was activated at 6-hours and 12-hours after hyperthermia. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T23:46:29Z (GMT). No. of bitstreams: 1 ntu-101-R99548016-1.pdf: 2598923 bytes, checksum: 80a622ba6f1d4a1404a2a5a0ba4c5c97 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 中文摘要 i
Abstract iii 目錄 v 圖目錄 viii 表目錄 xiii 第一章 緒論 1 1.1 前言 1 1.2 癌症 3 1.2.1 手術 4 1.2.2 化學療法 4 1.2.3 放射線療法 5 1.2.4 熱療 5 1.3 研究目的 7 第二章 文獻回顧 8 2.1 熱療 8 2.1.1 熱療方式 8 2.1.2 熱療機制 9 2.2 熱療用磁性顆粒 15 2.2.1 磁性顆粒 15 2.2.2 磁性顆粒加熱機制 17 2.3 熱休克蛋白 22 2.3.1 分子伴護蛋白 24 2.3.2 凋亡抑制因子 26 2.4 細胞死亡 31 2.4.1 凋亡 31 2.4.2 壞死 32 第三章 材料與方法 34 3.1 實驗儀器 34 3.2 實驗藥品 36 3.3 材料製備 39 3.4 材料分析 40 3.4.1 X 光粉末繞射儀 ( X-ray diffraction, XRD ) 40 3.4.2 超導量子干涉儀 41 3.5 材料生物相容性測試 43 3.5.1 WST-1 細胞活性測試 43 3.5.2 Lactate dehydrogenase 細胞死亡測試 43 3.6 體外測試 ( in vitro test ) 45 3.6.1 細胞內升溫速率 45 3.6.2 熱休克蛋白表現 45 3.7 細胞死亡 47 3.7.1 細胞膜外翻染色 ( annexin V-FITC / PI 染色 ) 47 3.7.2 DNA 斷裂染色 ( Terminal deoxynucleotidyl transferase -mediated dUTP nick-end-labeling, TUNEL / PI 染色 ) 48 3.7.3 procaspase-3 活化 49 第四章 結果與討論 50 4.1 磁性氫氧基磷灰石之性質分析 50 4.1.1 磁性氫氧基磷灰石之 X 光繞射圖譜 50 4.1.2 磁性氫氧基磷灰石之 M-H curve 51 4.2 磁性氫氧基磷灰石之體外測試 53 4.2.1 磁性氫氧基磷灰石於細胞內之升溫速率 53 4.2.2 磁性氫氧基磷灰石之生物相容性 56 4.2.3熱休克蛋白表現 61 4.3 細胞因磁性顆粒引發之熱療後之死亡 73 4.3.1 細胞膜外翻染色測試 73 4.3.2 DNA 斷裂染色測試 83 4.3.3 procaspase-3 活化 87 第五章 結論 89 第六章 參考文獻 91 | |
dc.language.iso | zh-TW | |
dc.title | 熱休克蛋白的分子機制 : 熱休克蛋白於磁性奈米顆粒引發之熱療的影響 | zh_TW |
dc.title | The molecular mechanism of heat shock protein : its impact on magnetic nanoparticles-induced hyperthermia therapy | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳克紹(Ko-Shao Chen),張淑真(Shwu-Jen Chang),郭士民(Shyh-Ming Kuo),侯君翰(Chun-Han Hou) | |
dc.subject.keyword | 磁性氫氧基磷灰石,熱療,熱休克蛋白,膜外翻,DNA 斷裂,procaspase-3 活化, | zh_TW |
dc.subject.keyword | magnetic hydroxyapatite ( mHAP ),hyperthermia,heat shock protein ( HSP ),cell membrane externalization,DNA fragmentation,procaspase-3 activation, | en |
dc.relation.page | 95 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-07-24 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
顯示於系所單位: | 醫學工程學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 2.54 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。